

KELLERHALS CARRARD ADVISES BVF PARTNERS ON ITS DEAL WITH NLS PHARMACEUTICS

Posted on 20 December 2022



Categories: [Capital Markets](#), [Corporate](#)

Tags: [BVF](#), [Kellerhals Carrard](#), [Kevin MacCabe](#), [Marc Hanslin](#), [Nicolas Mosimann](#), [NLS](#), [sx1](#)



As we have informed [here](#) **NLS Pharmaceuticals**, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that it has entered into a definitive agreement with funds managed by **BVF Partners**, a US fund manager, to raise aggregate gross proceeds of up to USD 30 million in a two-tranche private placement.

[Kellerhals Carrard](#) advised BVF on all Swiss legal aspects. The team consisted of partner **Nicolas Mosimann** (pictured), partner **Marc Hanslin** and **Kevin MacCabe** (all m&a/capital markets).